...
首页> 外文期刊>Melanoma research >The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines
【24h】

The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines

机译:泛极光激酶抑制剂PHA-739358诱导黑素瘤细胞系凋亡并抑制其迁移

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Treatment of metastatic melanoma has long been a challenge because of its resistance to traditional chemotherapeutics, leading to the search for alternative strategies. Aurora kinases are key mitotic regulators that are frequently overexpressed in various cancers including melanoma, making them ideal targets for drug development. Several Aurora kinase inhibitors have been developed and tested preclinically and clinically. PHA-739358 is currently one of the most advanced clinical compounds being tested in phase II clinical trials; however, its antitumor effect has not been tested in melanoma. In this study, the antiproliferative and anti-invasive effects of PHA-739358 were investigated in melanoma cell lines. The results demonstrated that PHA-739358 produces a time-dependent and dose-dependent inhibition of cell proliferation, induction of apoptosis, and inhibition of cell migration. Downregulation of matrix metalloproteinase-2 by the inhibition of NF??B-signaling pathway may contribute to PHA-739358-induced inhibition of migration. Furthermore, PHA-739358 enhanced temozolomide and Plx4032-induced apoptosis. This study suggests that Aurora kinase inhibitors may provide a new strategy for the treatment of advanced melanoma. ? 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
机译:转移性黑色素瘤的治疗长期以来一直是一个挑战,因为它对传统的化学疗法有抵抗力,导致人们寻找替代策略。 Aurora激酶是关键的有丝分裂调节剂,经常在包括黑色素瘤在内的各种癌症中过表达,使其成为药物开发的理想靶标。已经开发了几种Aurora激酶抑制剂并在临床前和临床上进行了测试。 PHA-739358是目前在II期临床试验中测试的最先进的临床化合物之一;但是,其抗肿瘤作用尚未在黑色素瘤中进行测试。在这项研究中,研究了PHA-739358在黑色素瘤细胞系中的抗增殖和抗侵袭作用。结果表明,PHA-739358对细胞增殖产生时间依赖性和剂量依赖性抑制,诱导细胞凋亡,并抑制细胞迁移。 NFκB信号通路的抑制下调基质金属蛋白酶2可能有助于PHA-739358诱导的迁移抑制。此外,PHA-739358增强了替莫唑胺和Plx4032诱导的细胞凋亡。这项研究表明,极光激酶抑制剂可能为晚期黑素瘤的治疗提供新的策略。 ? 2013威科集团健康|利平科特·威廉姆斯和威尔金斯。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号